Cancer patients get free genetic testing under Medicare, Medicaid
S. 755 — Finn Sawyer Access to Cancer Testing Act · Filed by Roger Wicker (R-MS) · 1 cosponsor · Introduced Feb 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare, Medicaid, and CHIP to cover advanced cancer diagnostic tests—including genetic sequencing and microarray analysis—at no or low cost to patients. Tests can be performed once at diagnosis, once at recurrence, and as needed for treatment planning. The bill also funds a public education program on genomic testing for doctors and patients.
Why we flagged it
The bill's primary function is to mandate insurance coverage of advanced cancer diagnostic tests under federal health programs. While named after an individual, the legislation is protective in intent—expanding access to diagnostic tools for cancer patients—not a vanity commemoration of a sitting official.
What the text implies
- Mandatory coverage beginning January 1, 2027 (not 2025 for Medicare/Medicaid) creates a 2-year lag; patients diagnosed before that date may not benefit, creating a cohort equity issue.
- CHIP coverage begins January 1, 2025—earlier than Medicare/Medicaid—suggesting potential political prioritization of pediatric/pregnancy-related cases.
The full analysis lists 5 implications of this text.
Who stands to gain
clinical laboratory companies; genomic testing providers; genetic counseling services